Journal of Neurochemistry

1.Cholesterol in the central nervous system (CNS) is largely unesterified (>99%) and is predominantly present in the myelin sheath ([~]70% of total CNS cholesterol). Damage to the myelin sheath can result in the conversion of cholesterol to cholesterol esters, which occurs in many neurological diseases, including multiple sclerosis. In this study, we measured longitudinal CNS free cholesterol and cholesterol ester levels in a genetic mouse model during postnatal myelination, demyelination, and remyelination using gas chromatography-mass spectrometry with single ion monitoring technique (GC-MS-SIM) and liquid chromatography mass spectrometry (LC-MS). Cholesterol levels in healthy mouse brains increased up to 38 weeks. In contrast, cholesterol in the healthy spinal cord increased during postnatal timepoints, but then remained steady out to 38 weeks. Interestingly, cholesterol esters in the spinal cord were highest at P1 and drastically reduced by P42, while the brain had similar levels during all postnatal time points. During demyelination, both brain and spinal cord cholesterol levels were significantly reduced as compared to healthy mice and failed to return to normal cholesterol levels even during remyelination. Absolute quantification of cholesterol esters during peak demyelination revealed that cholesterol esters comprise 19% of the total cholesterol pool in the brain and 65% in the spinal cord. The lack of recovery in CNS cholesterol levels after demyelination suggests that healthy de novo cholesterol synthesis pathways are disrupted in this model. Absolute quantification of CNS cholesterol is critical for revealing mechanisms of cholesterol regulation during disease and identifying targets for restoring cholesterol to promote myelin repair.

Spreading depolarizations (SDs) are waves of mass depolarization that propagate through gray matter following Na+/K+-ATPase (NKA) failure because of stroke, traumatic brain injury or sudden cardiac arrest. SDs expand the initial site of neuronal injury and worsen clinical outcomes. The molecular events underlying SD initiation and propagation are not well understood. In this rodent study, we hypothesized that gray matter stressed by oxygen/glucose deprivation (OGD) releases a compound(s) that promotes SD, which we term a spreading depolarization activator (SDa). We used rat brain slices incubated in artificial cerebrospinal fluid (aCSF) and subjected to OGD to release a putative SDa. The aCSF was collected either prior to ("Pre-SD aCSF") or 10 min after initiation of OGD conditions ("Post-SDOGD aCSF"). These solutions were then separately superfused over a healthy, naive (non-stressed) brain slice. Post-SDOGD aCSF (with re-normalized O2 and glucose) evoked SD in 82.35% of the naive brain slices (n = 17) whereas Pre-SD aCSF evoked no SD in 10 naive slices. Then to investigate the NKA as a potential target of the SDa, we used a hemolysis assay, comparing the effects of Pre- or Post-SDOGD aCSF on red blood cell (RBC) lysis and compared it to the known hemolytic effect of the NKA-specific inhibitor, palytoxin. Post-SDOGD aCSF evoked neither swelling nor lysis of RBCs on its own. However, when a sub-threshold concentration (0.01-0.02 nM) of the specific NKA inhibitor palytoxin (PLTX) was added, a striking "priming" effect was observed, whereby Post-SDOGD aCSF evoked a highly significant increase in both RBC swelling and then hemolysis, compared to Pre-SD aCSF. High pressure liquid chromatography (HPLC) experiments show a several-fold increase in released molecules post-SD vs pre-SD. Overall, this study provides support for SDa release capable of inducing SD-associated swelling in brain slices and, when combined with a trace amount of PLTX, swelling/hemolysis of RBCs caused by NKA inhibition. A greater understanding of the molecular events underlying SD should identify novel targets to reduce recurrent SD-evoked neuronal injury under ischemic conditions.

Brain-derived tau (BD-tau) is an emerging blood-based biomarker for neurodegeneration, yet there are currently limited well validated BD-tau assays available for research and clinical use. To enhance access to this vital biomarker for neurological disorders including traumatic brain injury (TBI), we developed a novel blood-based immunoassay for BD-tau on the ultra-sensitive Quanterix HD-X platform using Single Molecule Array technology. Analytical validation assessed dilution linearity, specificity, precision, detection limits, and spike recovery, each recording robust metrics in agreement with international expert recommendations. The assay demonstrated robust validation metrics, achieving between-run stability of 95% when analyzing aliquots from six independent plasma and serum samples across five analytical runs. It also showed strong dilution linearity when diluted four-fold and achieved over 90% recovery when spiked with cerebrospinal fluid. Next, we evaluated the clinical utility of the assay in cohorts of individuals with traumatic brain injury (TBI), where strong performances were recorded whether using the 2-step or 3-step assay formats ({rho}= 0.94; p < 0.0001). Furthermore, plasma BD-tau distinguished samples from TBI patients based on time from injury and severity (AUC=0.93). Plasma BD-tau differentiated between favorable and unfavorable functional outcomes in the acute-severe group. Our findings underscore the significant potential of the BD-tau assay as a biomarker for TBI in the severe phase.

The brain-nose interface is an anatomical junction where olfactory neurons from the olfactory bulb traverse the cribriform plate into the nasal mucosa, providing minimally invasive access to the central nervous system (CNS). We hypothesized that nasal fluid from this region could enable detection of neurology-relevant proteins using targeted multiplex assays. Using nosecollect, a targeted nasal sampling device, nasal fluid proximal to brain-nose interface was collected from cognitively impaired patients, alongside matched cerebrospinal fluid (CSF) and plasma. After nasal sample-specific dilution optimization and intra-assay precision evaluation, all matrices were profiled with the Olink Target 96 Neurology and NUcleic acid Linked Immuno-Sandwich Assay CNS disease 120 (NULISAseq CNS Disease 120) panels. Nasal fluid showed technically repeatable detection (intra-assay coefficient of variation <10% for more than 60% of proteins). Target detectability in nasal fluid (Olink 89/92; NULISA 121/131 proteins) was comparable to plasma and exceeded CSF. Numerous disease-relevant proteins were observed in nasal fluid, including brain-derived tau species, phosphorylated tau, alpha-synuclein, axonal and synaptic markers, and glial-microglial mediators. To our knowledge, this is the first neurology-focused characterization of the nasal proteome from the vicinity of brain-nose interface using targeted multiplex platforms and the first to profile matched nasal fluid, CSF, and plasma, supporting nasal fluid from brain-nose interface as an additional source for biomarker development.

Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions.

Reactive astrocytes contribute to neuroinflammation and synaptic dysfunction, but it remains unclear whether transient inflammatory stimulation causes a persistent reactive state after the initial inflammatory stimulus is removed. Here, we investigated whether transient exposure to a defined inflammatory cytokine/complement cocktail induces a persistent reactive astrocyte state and examined the signaling mechanism underlying its maintenance. Human astrocytes were exposed to the inflammatory stimulus and subsequently subjected to stimulus washout, followed by time-course analyses to compare the reversibility of inflammatory gene expression after stimulus removal. Following washout, the expression of several inflammatory response genes, including CXCL10 and NF-{kappa}B-associated genes such as NFKBIA, TNFAIP3, and RELB, returned toward baseline levels. In contrast, C3 expression remained elevated, indicating persistence of a post-inflammatory C3-high astrocyte state after withdrawal of the inflammatory stimulus. Pharmacological inhibition of JAK signaling reduced persistent C3 expression to near-baseline levels, supporting the involvement of JAK-dependent signaling in maintenance of this persistent state. Together, these findings suggest that transient inflammatory stimulation induces a post-inflammatory persistent C3-high astrocyte state that is maintained even after broader inflammatory gene responses have subsided. This persistent C3-high component is pharmacologically attenuated by JAK inhibition, identifying JAK-dependent pathways as modulators of persistent astrocyte inflammatory reactivity.

S-acylation is a reversible posttranslational lipid modification important in the nervous system that dynamically regulates protein localization and function. Aberrant S-acylation has been implicated in several neurological conditions. While several de-S-acylases (deacylases hereafter) have been identified, little is known regarding their expression and localization in the brain and in neurons. Here, we characterized the expression, localization, and S-acylation of cytosolic deacylases, including acyl-protein thioesterases APT, APT2, and APT1L and /{beta} hydrolase domain-containing proteins ABHD7, ABHD10, ABHD13, ABHD16A, and ABHD17A-C. Mouse brain RNA sequencing data revealed high expression of Lypla1/APT1, Lypla2/APT2, Ephx4/ABHD7, Abhd16a, and Abhd17A-C in the brain, whereas Lyplal1/APT1L, Abhd10, and Abhd13 were expressed at very low levels. Protein analysis demonstrated region-specific expression, with expression of APT1 and ABHD16A highest in the cerebellum and APT2 highest in the hippocampus, with all three highly expressed in cultured hippocampal neurons. Deacylases were observed distributed throughout neurons on punctate structures, with APT2 and ABHD17C to the Golgi by immunocytochemistry. Finally, all ten cytosolic deacylases are themselves S-acylated. These data characterizing deacylase expression, localization, and S-acylation in neural contexts, provides a foundation for future studies investigating deacylase neuronal functions and potential roles in neurological disease.

Cysteine proteome essentially regulates cellular adaptability during stress. Proteomic cysteines are reversibly modified to avoid loss through oxidation. Reversible cysteine-modifications beneficially preserve cellular stress-response mechanisms by regulating the transient activation of substrate proteins. Cysteine acylation (or s-acylation) is one such extensively documented reversible protein modification. Inflammation-responsive changes in s-acylation facilitate the plasticity of immune-partitioned brains by dynamically determining the utilization of stress-buffering (substrate) cysteine-proteins in microglia, the primary immune-reactive brain cells. However, the inflammation-responsiveness of cysteine-acylation in microglia is not elaborately measured at a large-scale. Therefore, we observed the differential (quantitative) s-acylation of proteins in cultured human (HMC3) microglia by implementing comparative MLCC-based chemoproteomic workflows. Parallelly, we characterized the molecular consequences of HMC3 cell treatment with 2-bromopalmitate, a general s-acylation inhibitor, by performing immunocytochemistry and proteomic experiments. We also identified the s-acylation-dependent microglial inflammatory responses through live spatiotemporal tracking and confocal microscopy, following treatment of microglia with PAMPs (LPS or IFNy). Finally, from our proteomic studies of postmortem human brain tissues, we confirmed major protein-causals of schizophrenia, a redox-related brain disorder, to undergo inflammation-responsive s-acylation. This report provides a first comprehensive library of cysteine-proteins differentially processed through inflammation-responsive acylation in microglia. It also outlines the inflammation-responsive s-acylation of key NRF2-antioxidants, including peroxiredoxins (especially PRDX2) and glutathione synthetase (GSS), as a biochemical signature of early-stage inflammation and oxidative-stress in microglia. More importantly, the innovative proteo-informatic workflows designed for this research work can be reliably repurposed to identify bifunctional theragnostic protein markers of many complex disorders and diseases.

Microglia are the brains resident immune cells that exhibit complex signaling behavior, including phagocytic activity in response to threats and prolonged neuronal activity. Adenosine triphosphate (ATP) is a chemoattractant for microglia. In the nucleus accumbens (NAc), ATP is co-packaged and released with DA, and microglia express dopamine (DA) receptors and ATP receptors. The present work examines microglia chemotactic motility for these transmitters using iontophoresis and multiphoton microscopy approaches in NAc brain slices from GFP-monocyte labeled transgenic mice. ATP chemoattraction was more regularly observed than DA chemoattraction, and DA chemoattraction occurred in only a small subset of microglia. The DA chemoattraction of this subset was blocked by DA D1 antagonism. Microglia are reactive oxygen species (ROS) scavengers. Application of glucose oxidase produces mild but consistent increases in ROS and induced inflammatory-related changes in microglial morphology and motility. Glucose oxidase application decreased DA release but had variable effects on ATP release. The toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) transitioned microglia from ramified to amoeboid morphology over a period of 4 hours, and increased DA and ATP release across this same period. These studies highlight the complex relationship between local immune activation and DA terminal functionality.

Parkinsons disease (PD) is associated with motor impairment and cortical synaptic dysfunction, which involve altered glutamate receptor trafficking, yet the underlying mechanisms remain incompletely understood. VPS26B, a component of the retromer complex, regulates GluA1 recycling in the trans-entorhinal cortex region. However, its role in the primary motor cortex (M1) under Parkinsonian conditions has not been explored. Here, we show that VPS26B levels are reduced in the M1 of an MPTP-induced PD mouse model, accompanied by decreased surface GluA1 and synaptic protein levels. VPS26B overexpression partially attenuated these alterations. In the accelerating rotarod test, VPS26B-deficient mice exhibited unstable motor performance following MPTP administration, whereas VPS26B overexpression was associated with improved performance in both wild-type and knockout mice. These findings suggest that cortical VPS26B may contribute to maintaining glutamate receptor surface expression and synaptic protein levels, especially under Parkinsonian conditions, with potential implications for motor learning.

Endosomal sorting complexes required for transport (ESCRT) regulate membrane protein trafficking through coordinated cargo selection and endosomal processing, yet their contribution to neurotransmitter receptor sorting remains to be defined. Here, we examined how modulation of distinct complex components influences the surface expression of excitatory and inhibitory neurotransmitter receptors. Using surface biotinylation and imaging approaches in heterologous cells and primary neurons, we altered tumour susceptibility gene 101 (TSG101), a core complex I component, and vacuolar protein sorting-associated protein 4A (VPS4a), an ATPase required for complex III disassembly. Reduction of tumour susceptibility gene 101 increased receptor association with early endosomes and enhanced receptor surface localisation, whereas disruption of VPS4A promoted receptor accumulation within late endosomal compartments and impaired degradative progression. Inhibitory receptor subtypes displayed variable sensitivity. Together, these findings demonstrate that endosomal sorting complex components regulate receptor surface expression through stage-specific trafficking mechanisms associated with altered receptor recycling and degradative processing. Graphical abstractDistinct ESCRT components regulate neurotransmitter receptor trafficking through stage-specific control of the endosomal pathway. ESCRT-I disruption promotes early endosomal retention and recycling, whereas ESCRT-III impairment causes late endosomal accumulation and reduced degradation, together increasing receptor surface expression (created using Biorender). O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=150 SRC="FIGDIR/small/732891v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@1fe66b9org.highwire.dtl.DTLVardef@10a29d7org.highwire.dtl.DTLVardef@4109c4org.highwire.dtl.DTLVardef@1e84f19_HPS_FORMAT_FIGEXP M_FIG C_FIG

Natural anti-NMDAR1 autoantibodies are present at varying levels in the general human population, but their effects on cognitive function remain unclear. Recent human studies reported significant associations between higher blood levels of natural anti-NMDAR1 autoantibodies and potential neuroprotective outcomes in Alzheimers disease, traumatic brain injury-associated depression and PTSD symptoms, and schizophrenia. However, whether these natural autoantibodies play a causal role in emotional and cognitive function has not been investigated. Since natural autoantibodies in human blood are predominantly of the IgM isotype, we immunized Aicda mutant mice to produce only IgM isotype anti-NMDAR1 autoantibodies without IgG and IgA isotypes. Mice were tested for sensorimotor gating and conditioned fear and extinction, cross species measures of information processing and emotional memory, respectively. Mice with higher levels of IgM anti-NMDAR1 autoantibodies exhibited significantly increased sensorimotor gating and improved fear extinction recall compared with mice with baseline levels of these autoantibodies. These findings indicate that IgM anti-NMDAR1 autoantibodies are pro-cognitive, unlike previous reports of poor cognition associated with IgG anti-NMDAR1 autoantibodies. Together, these studies suggest that IgM may hold therapeutic potential for a range of neurodegenerative, neurological, and psychiatric disorders.

D-Aspartate (D-Asp) is an endogenous D-amino acid that exhibits a pronounced developmental peak in the mammalian brain, suggesting a potential regulatory role in glutamatergic signaling and neurodevelopment. Disruption of D-Asp homeostasis has been associated with neuropsychiatric disorders characterized by early-life circuit vulnerability, including schizophrenia and autism spectrum disorders. However, its functional impact to hippocampal physiology remains incompletely defined. Here, we investigated how constitutive D-Asp depletion affects synaptic function in the hippocampal CA1 region of Ddo-knock-in (Ddo-KI) mice, in which zygotic overexpression of the D-Asp-degrading enzyme, D-aspartate oxidase (DASPO), results in embryonic and persistent D-Asp deficiency. Electrophysiological recordings were performed in acute hippocampal slices from male and female mice at postnatal day 30 (P30) and day 60 (P60). Basal synaptic transmission, assessed through paired-pulse ratio and spontaneous excitatory/inhibitory events, was unaltered between genotypes, indicating preserved presynaptic release probability and overall excitation/inhibition balance. In contrast, NMDA receptor (NMDAR)-dependent synaptic plasticity was selectively altered, as theta-burst stimulation induced significantly greater long-term potentiation (LTP) in juvenile P30 Ddo-KI mice, whereas this difference was no longer observed at P60. Consistently, patch-clamp recordings revealed a reduced AMPAR/NMDAR ratio in P30 Ddo-KI males, suggesting an increased relative contribution of NMDAR-mediated currents. Importantly, acute bath application of exogenous D-Asp restored LTP to wild-type levels, demonstrating rapid reversibility and supporting a model of homeostatic receptor rebalancing rather than irreversible circuit alterations. Biochemical assays confirmed significantly increased DASPO activity and reduced D-Asp levels in Ddo-KI mice. However, these parameters remained stable between P30 and P60, indicating that the age-dependent plasticity phenotype is unlikely to arise from progressive biochemical changes. Together, these findings indicate that developmental D-Asp deficiency induces a transient, juvenile-specific alteration characterized by enhanced NMDAR-dependent synaptic plasticity, which can be rapidly normalized upon D-Asp re-exposure.

Statins, widely used cholesterol-lowering drugs, inhibit the mevalonate pathway and reduce coenzyme Q (CoQ) biosynthesis, potentially impairing mitochondrial function. Because astrocytes are essential for maintaining brain redox homeostasis, statin-induced mitochondrial dysfunction in these cells may contribute to CNS pathology. We examined the effects of a six-day statin exposure on mitochondrial bioenergetics in rat astrocytes, focusing on mitochondrial CoQ (mtCoQ) deficiency. Treatment with 200 nM atorvastatin or simvastatin decreased the total mtCoQ pool (mtCoQ9 + mtCoQ10) by 30-35% and decreased the antioxidant pool mtCoQH2 by 40%, whereas the levels of mitochondrial antioxidant proteins, including superoxide dismutase 2 and uncoupling proteins, remained unchanged. Mitochondria of statin-treated astrocytes showed decreased respiratory activity, membrane potential, and ATP synthesis, and increased mtCoQ reduction leading to increased H2O2 production during the oxidation of complex I (CI) and CII substrates. Statin treatment also altered the organization of the respiratory chain, leading to a downregulation of the CI+CIII2+CIV and CIII2+CIV supercomplexes and decreased protein levels and activity of all respiratory chain complexes. Furthermore, a decrease in cytochrome a + a3 content was accompanied by a reduction in the maximum activity of CIV. CoQ10 supplementation elevated mtCoQ levels, restored respiratory function, and decreased H2O2 production in the mitochondria of statin-treated astrocytes. Prolonged statin exposure alters mtCoQ redox homeostasis and impairs mitochondrial bioenergetic function in astrocytes. CoQ10 supplementation attenuates these changes, supporting its potential role in protecting astrocyte mitochondria from statin-induced dysfunction.

The accumulation of amyloid-beta (A{beta}) plaques is a hallmark of Alzheimers disease (AD), with A{beta}42 representing the predominant and most aggregation-prone isoform. Reliable preparation of monomeric A{beta}42 is essential for investigating the kinetics and mechanisms of its aggregation into oligomers and fibrils. This study provides a direct comparison of two monomerization protocols for recombinantly expressed A{beta}42: one incorporating size-exclusion chromatography (SEC) and the other relying solely on chemical denaturation, using agents such as NaOH and NH4OH. A{beta}42 was produced in E. coli, purified through urea solubilization followed by HPLC, and subjected to monomerization via the respective methods. Monomeric preparations were evaluated using Thioflavin T (ThT) fluorescence to assess aggregation kinetics, TEM to detect fibrils and preformed aggregates, and NMR spectroscopy. SEC-isolated monomers displayed sigmoidal aggregation profiles in ThT assays, featuring distinct lag, growth, and plateau phases consistent with secondary nucleation-dominated models as determined by AmyloFit analysis. Increasing the initial peptide concentration resulted in higher fibril yields, which was further supported by TEM images showing extensive fibrillization following incubation. In contrast, non-SEC preparations containing pre-existing aggregates detectable by TEM and showed attenuated NMR signals, leading to impaired aggregation behavior. NaOH-denatured samples predominantly exhibited flat ThT curves, whereas NH4OH-denatured samples displayed extended lag phases. NH4OH performance better than NaOH, likely because its gradual pH neutralization reduced peptide structural perturbation. Overall, these findings demonstrate that SEC is critical for obtaining highly pure monomeric A{beta}42 and improving the reproducibility of aggregation assays, highlighting the importance of standardized monomer preparation protocols in AD research. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=49 SRC="FIGDIR/small/724608v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@1a3b9caorg.highwire.dtl.DTLVardef@1fa85d2org.highwire.dtl.DTLVardef@67a83dorg.highwire.dtl.DTLVardef@1564f77_HPS_FORMAT_FIGEXP M_FIG C_FIG

Tonic glutamate signaling by ambient levels of extracellular glutamate has been implicated in development, brain injury, pathologies, and physiological activity. However, it has been difficult to assay extracellular glutamate changes with spatial and temporal resolution. Here, we utilize the rarely used ratiometric excitations properties of the fluorescence glutamate sensor iGluSnFr to enable the characterization of ambient glutamate levels in acute brain slices. This ratiometric imaging enables a spatial, temporal and calibratable assay of ambient glutamate and demonstrates regional differences in ambient glutamate and sensitivity to glutamate transporters and system Xc inhibition.

Mitochondrial morphology and function are critical determinants of neuronal function and survival, with disruptions in mitochondrial dynamics often preceding the overt neuronal dysfunction seen in neurodegenerative diseases such as Alzheimers disease, Huntingtons disease and Parkinsons disease. The kynurenine pathway accounts for 95% of dietary tryptophan catabolism and many of the metabolites are neuroactive, including redox-active 3-hydroxykynurenine (3-HK). 3-HK is present under normal physiological conditions in the central nervous system (CNS) and is elevated during inflammation. While supraphysiological levels of 3-HK have been associated with neurotoxicity, the effects of physiological concentrations on neuronal cells, and specifically their mitochondria, remain poorly understood. Here we assessed viability, ATP levels and redox status to determine cellular health and function in neuronal cells exposed to physiological levels of 3-HK, alongside confocal imaging and transcriptomic profiling, finding significant alterations in mitochondrial function and morphology. Interestingly, a biphasic influence of 3-HK on mitochondrial morphology was observed, with an elongated network as well as decreased surface area and volume being observed only at the lowest concentration of 3-HK, reflecting normal physiological levels. At the highest 3-HK concentration tested, reflecting an inflammatory situation, an increased number of mitochondria were present, accompanied by increased activation of caspase-3/7 and enhanced production of mitochondrial superoxide. These results highlight a previously unknown role for 3-HK in regulating mitochondrial function and structure, possibly through altered fission and fusion events, suggesting that subtle changes in kynurenine pathway metabolism may contribute to early mitochondrial dysfunction in neurological disease.

Blood-based biomarkers are increasingly used to investigate brain health, but collecting venous blood is difficult in remote and field settings. Capillary microsampling offers a practical alternative, although the ability to delay processing and its agreement with gold-standard venous blood require validation. We evaluated Tasso+, a minimally invasive upper-arm capillary blood collection system, for measuring neurological and host-response biomarkers in plasma and serum during an exercise-based protocol. Sampling occurred before, immediately after, and approximately 24-to-36 hours after exercise; Tasso+ samples were processed with or without a 72-hour room-temperature delay. Tasso+ samples were compared with matched venous blood, and Capitainer SEP10 dried plasma spots were also evaluated, using Quanterix Simoa and Alamar Biosciences NULISAseq CNS panel. Tasso+ enabled reliable measurement of several key biomarkers, including GFAP and NfL, even after delayed processing. These findings support capillary microsampling for neurological biomarker studies where venepuncture is challenging, including field-based research and participant-led remote sampling.

A multi-omic approach utilizing a single biospecimen is important to avoid intra-sample heterogeneity associated with testing multiple omic single-samples, and for more efficient use of small volumes of precious biopsies (<30 mg). This is especially true for the microanatomy of post-mortem human brain samples. Using post-mortem human brain biospecimens from the NIH NeuroBioBank, a penta-omic sequential extraction method is described, Simultaneous Metabolomic, Proteomic, Lipidomic - DNA, RNA Extraction (SiMPL-DREx). Each sequential omic extract was compared to those obtained by the gold standard single omic method. Preserving RIN is critical for brain and tissue banks, as it is a primary measure of tissue quality. For all five omic extracts, the tissue integrity numbers and omic profiles did not significantly differ from those obtained by the respective omic gold standard method. Unlike past multi-omic studies, this study quantified the relative solvent percentages and upstream losses for both the organic and aqueous phases, confirming an omics loss of under 5%.

The leptomeninges (arachnoid and pia) are the inner layers of the meninges that envelope the brain. They define the borders of the subarachnoid space (SAS) where cerebrospinal fluid (CSF) circulates. Leptomeninges act as the barrier tissue and contribute to fluid exchange and immune function of the brain. These processes are identified as key factors in the development of neurodegenerative diseases. The extracellular matrix (ECM) is a critical structural component of leptomeninges. However, it remains insufficiently characterized in health and disease. Here, we performed complete proteomic profiling of ECM proteins (matrisome) of human leptomeninges from individuals with Alzheimers disease (AD) and cognitively normal controls (CN) using sequential biochemical fractionation coupled with mass spectrometry. We resolved leptomeningeal matrisome based on the biochemical properties reflected by the protein solubility. This approach identified 211 ECM proteins in human leptomeninges and revealed disease-associated shifts in leptomeningeal solubility consistent with altered matrix organization and signaling. We found that ECM-linked regulators and secreted factors extracellular sulfatase SULF2, antithrombin-III (SERPINC1), secreted frizzled-related protein 3 (sFRP3) and integrin beta-5 (ITGB5), which is a receptor for fibronectin, were differentially expressed in AD leptomeninges based on the disease status. Seven ECM proteins were identified only in AD samples, and two ECM proteins in CN samples. Pathway enrichment implicated TGF-{beta} and Wnt-related signaling and coagulation as critical for leptomeningeal function. Our findings provide the first comprehensive proteomic characterization of the human leptomeningeal matrisome and establish a biochemical framework for investigating how meningeal matrix remodeling contributes to AD.